Tissue Debate Raises Fairness, Transparency Questions For Combo Products
This article was originally published in The Gray Sheet
Executive Summary
CDRH's decision to require 510(k) submissions for demineralized bone matrix (DBM) products is at odds with previous policy statements by the Center for Biologics Evaluation & Research, the American Association of Tissue Banks maintains in comments sent to the FDA center directors April 19